Week in Review: DXY Receives $70 Million Investment from Tencent

DXY Group, China's largest healthcare portal, received a $70 million investment from Tencent Holdings, a China internet and mobile phone services company; GC-Rise Pharma of Beijing closed a $15 million Series B financing from OrbiMed for its China in-licensing business; Eddingpharm paid $2.3 million for China rights to an Ablynx TNF treatment for rheumatoid arthritis; Zhejiang Huahai and Tianjin Pharma signed a framework agreement to jointly develop products for the US market; Hainan Sinotau Pharma gained China rights to a Navidea radiopharmaceutical; a Fosun subsidiary will collaborate with CleveXel Pharma of France to increase production of a malaria drug; BeiGene of Beijing signed up for CMO services from Boehringer Ingelheim's new Shanghai biopharma facility; NovaBay's wound cleanser, which will be distributed by China Pioneer, was cleared for China sale by the CFDA; and Tasly officially opened its North American headquarters in Maryland. More details.... Stock Symbols: (HK: 00700) (BR:ABLX) (SHA: 600521)  (NYSE: NAVB) (SHA: 600196; HK: 2196) (SHA: 600535) (NYSE: NBY) Share this with colleagues: // //